The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 08, 2013
Filed:
Nov. 28, 2007
Martina Fatho, Wörrstadt, DE;
Emmanuelle Wesarg, Darmstadt, DE;
Volker Lennerz, Ober-Olm, DE;
Pierre Van Der Bruggen, Brussels, BE;
Thomas Wölfel, Mainz, DE;
Serena Debo, Mainz, DE;
Martina Fatho, Wörrstadt, DE;
Emmanuelle Wesarg, Darmstadt, DE;
Volker Lennerz, Ober-Olm, DE;
Pierre Van Der Bruggen, Brussels, BE;
Thomas Wölfel, Mainz, DE;
Serena Debo, Mainz, DE;
Johannes Gutenberg-Universitat Mainz, Mainz, DE;
Abstract
The present invention relates to a method for identifying the preferential target antigens of antitumoural T-cells of a tumour patient, comprising: a) providing T-cells from the blood of at least one tumour patient, b) providing dendritic cell (DCs) and/or B-lymphocytes (BLCs) that are autologous for said tumour patient, wherein said DCs and BLCs were transfected beforehand with a selection of mRNAs encoding for T-cell-immunogenic tumour-associated antigens (TAA), and express these, c) contacting said T-cells with the DCs and/or BLCs, d) identifying of those T-cells that recognize antigens of the DCs and/or BLCs, and e) identifying of the preferential target antigens of antitumoural T-cells of the at least one tumour patient on the basis of the T-cells that recognize antigens of the DCs and/or BLCs. The method can furthermore comprise the expansion of the T-cells that recognize the antigens of the DCs and/or BLCs. The present invention furthermore relates to a method for producing an individualized tumour vaccine or individualized tumour therapeutic, as well as corresponding methods for treating a tumourous disease using the individualised tumour vaccine or individualised tumour therapeutic.